Novakand Pharma to Acquire SVF Vaccines in All-Share Deal Valued at 55 MSEK
I'm PortAI, I can summarize articles.
Novakand Pharma AB has agreed to acquire SVF Vaccines AB in an all-share deal valued at approximately 55 million SEK, issuing 242,372,493 new shares. Post-transaction, Novakand shareholders will own 33.3% and SVF shareholders 66.7% of the combined entity. The deal requires approval from an Extraordinary General Meeting, Nasdaq listing, and regulatory clearance, with a target closure before Q1 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments